title: Editorial commentary: rifampicin plus colistin in the era of extensively drug-resistant Acinetobacter baumannii infections.
authors.forename: Timothy P
authors.initials: TP
authors.lastname: Gauthier
mesh_terms: D000151:Acinetobacter Infections / Q000188:drug therapy*; D040981:Acinetobacter baumannii / Q000187:drug effects*; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D003091:Colistin / Q000627:therapeutic use*; D024901:Drug Resistance, Multiple, Bacterial; D005260:Female; D006801:Humans; D008297:Male; D012293:Rifampin / Q000627:therapeutic use*
chemical_list: D000900:Anti-Bacterial Agents; D012293:Rifampin; D003091:Colistin
keywords: Acinetobacter baumannii; antimicrobial resistance; colistin; rifampicin